- Home
- GLRE vs NGNE Comparison
GLRE vs NGNE Comparison
Compare GLRE & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- NGNE
- Stock Information
- Founded
- GLRE 2004
- NGNE 2003
- Country
- GLRE Cayman Islands
- NGNE United States
- Employees
- GLRE N/A
- NGNE N/A
- Industry
- GLRE Property-Casualty Insurers
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- GLRE Finance
- NGNE Health Care
- Exchange
- GLRE Nasdaq
- NGNE Nasdaq
- Market Cap
- GLRE 439.8M
- NGNE 426.6M
- IPO Year
- GLRE 2007
- NGNE N/A
- Fundamental
- Price
- GLRE $12.93
- NGNE $21.74
- Analyst Decision
- GLRE
- NGNE Strong Buy
- Analyst Count
- GLRE 0
- NGNE 6
- Target Price
- GLRE N/A
- NGNE $38.50
- AVG Volume (30 Days)
- GLRE 127.7K
- NGNE 273.6K
- Earning Date
- GLRE 11-03-2025
- NGNE 11-13-2025
- Dividend Yield
- GLRE N/A
- NGNE N/A
- EPS Growth
- GLRE N/A
- NGNE N/A
- EPS
- GLRE N/A
- NGNE N/A
- Revenue
- GLRE $661,540,000.00
- NGNE N/A
- Revenue This Year
- GLRE N/A
- NGNE N/A
- Revenue Next Year
- GLRE N/A
- NGNE N/A
- P/E Ratio
- GLRE N/A
- NGNE N/A
- Revenue Growth
- GLRE N/A
- NGNE N/A
- 52 Week Low
- GLRE $11.57
- NGNE $6.88
- 52 Week High
- GLRE $15.38
- NGNE $37.27
- Technical
- Relative Strength Index (RSI)
- GLRE 56.99
- NGNE 36.74
- Support Level
- GLRE $11.57
- NGNE $23.93
- Resistance Level
- GLRE $13.35
- NGNE $32.02
- Average True Range (ATR)
- GLRE 0.34
- NGNE 3.09
- MACD
- GLRE 0.08
- NGNE -1.31
- Stochastic Oscillator
- GLRE 79.83
- NGNE 2.64
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.